Cannabis Pharmaceuticals Market Report 2026

Cannabis Pharmaceuticals Market Overview

• Cannabis Pharmaceuticals market size has reached to $9.43 billion in 2025 • Expected to grow to $85.68 billion in 2030 at a compound annual growth rate (CAGR) of 55.3% • Growth Driver: Increasing Epilepsy Cases Boost Demand For Cannabis-Based Treatments • Market Trend: Advancing Medical Cannabis Production To Meet Global Demand • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cannabis Pharmaceuticals Market?

Cannabis pharmaceuticals are prescription-grade medications made from cannabis-derived compounds, designed to address particular health conditions and produced under strict clinical and regulatory standards. These pharmaceuticals utilize the therapeutic benefits of cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), to treat conditions including chronic pain, epilepsy, and multiple sclerosis. The main indications in the cannabis pharmaceuticals include cannabinoid-based pharmaceuticals, cannabis extracts, and synthetic cannabinoids. Cannabinoid-based pharmaceuticals are drugs that incorporate synthetic or natural cannabinoids, such as THC and CBD, to address various health conditions. The various formulation types are capsules and tablets, oils and tinctures, and topical solutions used in therapeutic applications such as cancer, neurological disorders, and pain management. The various distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies and are used by several end users, including hospitals and clinics, rehabilitation centers, and research organizations.

What Is The Cannabis Pharmaceuticals Market Growth Forecast?

The cannabis pharmaceuticals market size is expected to see exponential growth in the next few years. It will grow to $85.68 billion in 2030 at a compound annual growth rate (CAGR) of 55.3%. The growth in the forecast period can be attributed to increasing investments in cannabis drug clinical trials, rising demand for standardized cannabinoid formulations, expansion of neurological and oncology applications, growing adoption of cannabis pharmaceuticals in hospitals, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing development of prescription-grade cannabis medications, rising focus on clinical validation and trials, growing use in neurological and pain disorders, expansion of regulated pharmaceutical pipelines, enhanced emphasis on dosage precision.

What Is The Driver Of The Cannabis Pharmaceuticals Market?

The rise in incidence of epilepsy is expected to drive the cannabis pharmaceuticals market going forward. Epilepsy refers to a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. The rise in epilepsy cases can be attributed to better diagnosis, increased awareness, and enhanced reporting, alongside potential environmental, genetic, and lifestyle influences. Cannabis pharmaceuticals have shown potential in helping manage epilepsy by utilizing cannabinoids like CBD to reduce the frequency and severity of seizures in patients who do not respond well to traditional anti-epileptic drugs. For instance, in February 2024, according to the World Health Organization, a Switzerland-based global health agency, the number of people living with epilepsy worldwide has risen to approximately 50 million in 2024. Therefore, the rise in incidence of epilepsy is driving the growth of the cannabis pharmaceuticals industry.

Key Players In The Global Cannabis Pharmaceuticals Market

Major companies operating in the cannabis pharmaceuticals market are Tilray Inc., Canopy Growth Corporation, Aurora Cannabis Inc., Aphria Inc., Cronos Group, GW Pharmaceuticals plc, Jazz Pharmaceuticals plc, Organigram Holdings Inc., Aleafia Health Inc., Avicanna Inc., Enveric Biosciences Inc., Auxly Cannabis Group Inc., Emerald Health Therapeutics Inc., Medical Marijuana Inc., Valens Company Inc., Curaleaf Holdings Inc., Trulieve Cannabis Corp., Green Thumb Industries Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc.

Global Cannabis Pharmaceuticals Market Trends and Insights

Major companies operating in the cannabis pharmaceuticals market are focusing on developing innovative products such as advanced medical cannabis formulations to address a range of medical conditions and improve patient outcomes. Advanced medical cannabis formulations refer to specially designed cannabis-based products that are optimized for therapeutic use, incorporating precise doses of cannabinoids like THC and CBD. For instance, in April 2024, Canexis Pharma AG, a Switzerland-based pharmaceutical company, received manufacturing and narcotics licenses from Swissmedic for cannabis pharmaceuticals. These approvals empower the company to produce premium-grade medicinal active ingredients derived from CBD and THC. This development positions Canexis to meet the growing demand for medical cannabis both within Switzerland and globally. By obtaining these licenses, the company demonstrates its compliance with stringent regulatory standards, enhancing its credibility and ability to contribute to the rapidly evolving medical cannabis market.

What Are Latest Mergers And Acquisitions In The Cannabis Pharmaceuticals Market?

In September 2025, High Tide, a Canada-based cannabis and wellness company, acquired a majority stake in Remexian Pharma GmbH, for an undisclosed amount. With this acquisition, High Tide aims to expand its pharmaceutical and wellness portfolio, enhance its product development capabilities, strengthen its European market presence, and drive long-term growth and strategic synergies. Remexian Pharma GmbH is a Germany-based pharmaceutical company specializing in the development and production of innovative healthcare solutions.

What Defines the Cannabis Pharmaceuticals Market?

The cannabis pharmaceuticals market consists of sales of dronabinol (synthetic THC) and cannabidiol (CBD) oil used to treat various medical conditions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cannabis Pharmaceuticals Market Report 2026?

The cannabis pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cannabis pharmaceuticals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.